Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067093 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,452
- Enrollment target
NCT00067093: Completed Phase 3 study, sponsored by Sanofi.
NCT00067093 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 1,452 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00067093, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,452 participants
- Enrollment target
Study Summary
Patients who have deep vein thrombosis (blood clot in the leg) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood thinning) drug administered once each week, SanOrg34006, with the standard way of treating deep vein thrombosis. The standard treatment includes injections or infusions of an anticoagulant drug (Unfractionated Heparin or low molecular weight heparin) for about a week, followed by vitamin K antagonist (VKA) anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth. Eligible patients will be assigned to treatment with either SanOrg34006 or the combination of Unfractionated Heparin or low molecular weight heparin plus a VKA (warfarin or acenocoumarol) by random chance. Treatment will be known to both patients and their doctors.
Interventions
- DRUG Vitamin K antagonist (VKA)
- DRUG Unfractionated heparin
- DRUG SanOrg34006
- DRUG LMW heparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,452 participants |
| Start Date | 2003-05 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
What the finished NCT00067093 record still lists
NCT00067093 is an interventional study that assigns participants to a tested intervention. Its 1,452 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% higher).
The record links to 0 conditions, and to 4 interventions - of which Vitamin K antagonist (VKA) is the first listed.
NCT00067093 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00067093 about?
NCT00067093 is a clinical study titled "Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)". Patients who have deep vein thrombosis (blood clot in the leg) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood thinning) drug administered once each week, SanOrg34006, with the standard way of treating deep v...
What is the current status of trial NCT00067093?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,452 participants. The study started on 2003-05. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00067093?
The interventions under investigation include: Vitamin K antagonist (VKA) (DRUG), Unfractionated heparin (DRUG), SanOrg34006 (DRUG), LMW heparin (DRUG).
Who is sponsoring clinical trial NCT00067093?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00067093's enrollment target sits among peer trials
1,452 166th of 2000 higher than 1,835 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
- NCT05910268 · 1,450 participants · NA
Peru Decentralized HIV Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia